CD86 and neoplasm: SUP3 was shown to enhance cross-presentation by CD8+ cDCs in vitro, up-regulate the expression of CD40 and CD86 co-stimulatory molecules and induce production of IL-6 and TNFα in DC, culminating in an antigen-specific CD8+ T cell response and increased immunization against tumor challenge.